Search
Tolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedBy the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.
Categories: Cytochrome P-450 Substrates, Non COX-2 selective NSAIDSProducts: TOLFEDINE 4% W/V SOLUTION FOR INJECTION FOR DOGS AND CATS, Tolfine Solution for Injection 4.0% W/VBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalIt offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingMelperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalThis drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970] … Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingEfonidipine
go.drugbank.com/drugs/DB09235InvestigationalThis drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingMoxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnMoxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.
Categories: Heterocyclic Compounds, 1-Ring, Adrenergic alpha-2 Receptor AgonistsSynonyms: (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acidIproclozide
go.drugbank.com/drugs/DB09247ApprovedWithdrawnAlthough it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnCaroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. … However, it presents a five-fold preference for the MAO-B subtype.
Categories: Heterocyclic Compounds, 1-RingBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnLike semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class [A7866]. … Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH).
Products: HIBOR 10000 IU/0,4 ML SC KULLANIMA HAZIR ENJEKTÖR, 2 ADET, HIBOR 5000 IU/0,2 ML SC KULLANIMA HAZIR ENJEKTÖR, 2 ADETIdarucizumab
go.drugbank.com/drugs/DB09264ApprovedIdarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease
Products: PRAXBIND®, PRAXBİND 50 MG/ML ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ, 2 ADET